QUEBEC CITY, April 23, 2021 / CNW / - Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce that Health Canada has accepted the first part of the continuous review request for its adjuvanted vaccine candidate against COVID-19 produced on plants.

The continuous review process, offered under an interim order, allows Medicago to submit non-clinical sections along with quality, safety and efficacy information to Health Canada as it becomes available. become available. An approach that speeds up the overall review process. However, Health Canada does not decide on the authorization of a candidate vaccine against COVID-19 until it has obtained all the data to support a decision related to the risk-benefit profile based on safety. efficiency and quality.

"Health Canada's decision to accept Medicago's request for continuous review of the vaccine, a first for a COVID-19 vaccine made in Canada, represents an important first milestone for us," said Carolyn Finkle, chief of staff. operation at Medicago. We are very grateful and also look forward to continuing our collaboration with Health Canada as the ongoing review of our COVID-19 vaccine begins under the Interim Order. "

 

For more details....